|
|
|
|
| MC543a | Multiple organ cancer tissue array, including pathology grade, TNM and clinical stage, 54 cases/54 cores, replacing MC543 | | Cores | 54 | Cases | 54 | | Row number | 6 | Column number | 9 | | Core Diameter(mm) | 1.5 | Thickness(µm) | 5.0 | | Tissue Array Type | FFPE | Species | Human | | QA/QC | H&E and IHC confirmed | | Applications | Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page. | | Notes | 1.Please keep the slides at 4 ℃ after receiving, and make experiment within 3 months will be better. 2.Bake the slides for 60 minutes at 65℃ before the experiment. 3.Please choose a gentle repair method to avoid tissue detachment. |
|
|
| |
|
Legend:
|
Thy -Thyroid gland Ski -Skin Pro -Prostate Per -Pericardium Ret -Retroperitoneum Pan -Pancreas Ova -Ovary Lun -Lung Liv -Liver Kid -Kidney Eye -Eye Sto -Stomach Eso -Esophagus Bra -Brain Bre -Breast Cer -Cervix Bla -Bladder Rec -Rectum Col -Colon Bon -Bone III -III Ton -Tongue |
Malignant (*) Malignant (I) Malignant (IB) Malignant (II) Malignant (IIA) Malignant (IIB) Malignant (III) Malignant (IIIA) Malignant (IV) |
|
|
|
| |
| Pos | No | Age | Sex | Organ_Anatomic_Site | Pathology_diagnosis | Grade | TNM | Stage | Type |
| A1 | 1 | 33 | F | Kidney | Papillary carcinoma | * | T2N0M0 | II | Malignant |
| A2 | 2 | 35 | M | Kidney | Papillary carcinoma | * | T1N1M0 | III | Malignant |
| A3 | 3 | 39 | M | Kidney | Chromophobe cell carcinoma | * | T2N0M0 | II | Malignant |
| A4 | 4 | 68 | F | Kidney | Chromophobe cell carcinoma | * | T1N0M0 | I | Malignant |
| A5 | 5 | 28 | F | Thyroid gland | Papillary carcinoma | * | T3N1M0 | I | Malignant |
| A6 | 6 | 30 | M | Thyroid gland | Papillary carcinoma | * | T3N1M0 | I | Malignant |
| A7 | 7 | 52 | F | Lung | Papillary adenocarcinoma | 2 | T3N1M0 | IIIA | Malignant |
| A8 | 8 | 72 | M | Lung | Lepidic predominant invasive adenocarcinoma | * | T3N0M0 | IIB | Malignant |
| A9 | 9 | 61 | F | Pancreas | Adenocarcinoma | 3 | T2N0M0 | IB | Malignant |
| B1 | 10 | 41 | M | Pancreas | Adenocarcinoma | 2 | T4N1M0 | III | Malignant |
| B2 | 11 | 35 | F | Tongue | Squamous cell carcinoma | 1 | T2N0M0 | II | Malignant |
| B3 | 12 | 45 | M | Tongue | Squamous cell carcinoma | 1 | T4N1M0 | IV | Malignant |
| B4 | 13 | 45 | F | Tongue | | | | | |
| B5 | 14 | 2 | T3 | III | Doc120124 | Malignant | | | |
| B6 | 15 | 39 | M | Brain | Astrocytoma | 2 | * | * | Malignant |
| B7 | 16 | 55 | F | Brain | Astrocytoma | 2 | * | * | Malignant |
| B8 | 17 | 56 | F | Bone | Plasma cell myeloma | * | * | * | Malignant |
| B9 | 18 | 69 | M | Bone | Plasma cell myeloma | * | * | * | Malignant |
| C1 | 19 | 53 | M | Colon | Mucinous adenocarcinoma | 1 | T2N0M0 | I | Malignant |
| C2 | 20 | 54 | M | Colon | Adenocarcinoma | 1 | T3N0M0 | IIA | Malignant |
| C3 | 21 | 53 | F | Rectum | Adenocarcinoma | 2 | T4N1M1 | IV | Malignant |
| C4 | 22 | 51 | F | Bladder | High grade urothelial carcinoma | * | T2bN0M0 | II | Malignant |
| C5 | 23 | 60 | M | Bladder | High grade urothelial carcinoma | * | T3N0M0 | III | Malignant |
| C6 | 24 | 52 | F | Cervix | Squamous cell carcinoma | 2 | T1N0M0 | I | Malignant |
| C7 | 25 | 48 | F | Cervix | Squamous cell carcinoma | 2 | T2N0M0 | II | Malignant |
| C8 | 26 | 65 | F | Breast | Invasive carcinoma of no special type | 2 | T2N1M0 | IIB | Malignant |
| C9 | 27 | 63 | F | Breast | Invasive carcinoma of no special type | 2 | T2N0M0 | IIA | Malignant |
| D1 | 28 | 48 | F | Brain | Astrocytoma | 3 | * | * | Malignant |
| D2 | 29 | 17 | M | Brain | Glioblastoma | 4 | * | * | Malignant |
| D3 | 30 | 68 | M | Esophagus | Squamous cell carcinoma | 2 | T3N0M0 | IIA | Malignant |
| D4 | 31 | 62 | M | Esophagus | Squamous cell carcinoma | 1 | T3N0M0 | IIA | Malignant |
| D5 | 32 | 40 | F | Stomach | Adenocarcinoma | 3 | T3N0M0 | IIA | Malignant |
| D6 | 33 | 48 | M | Stomach | Adenocarcinoma | 1 | T3N2M0 | IIIA | Malignant |
| D7 | 34 | 41 | F | Eye | Malignant melanoma of choroid | * | * | * | Malignant |
| D8 | 35 | 37 | M | Eye | Malignant melanoma | * | * | * | Malignant |
| D9 | 36 | 72 | F | Kidney | Clear cell carcinoma | 1 | T1N0M0 | I | Malignant |
| E1 | 37 | 82 | M | Kidney | Clear cell carcinoma | 3 | T1N0M0 | I | Malignant |
| E2 | 38 | 45 | M | Liver | Hepatocellular carcinoma | 2 | T2N0M0 | II | Malignant |
| E3 | 39 | 40 | M | Liver | Hepatocellular carcinoma | 2 | T3N1M0 | IV | Malignant |
| E4 | 40 | 53 | M | Lung | Squamous cell carcinoma | 1--2 | T2N1M0 | IIA | Malignant |
| E5 | 41 | 58 | M | Lung | Squamous cell carcinoma | 3 | T2N1M0 | IIA | Malignant |
| E6 | 42 | 36 | F | Ovary | Serous adenocarcinoma | 3 | T2N0M0 | II | Malignant |
| E7 | 43 | 50 | F | Ovary | Serous adenocarcinoma | 3 | T1N0M0 | I | Malignant |
| E8 | 44 | 54 | M | Pancreas | Duct adenocarcinoma | * | T2N0M0 | IB | Malignant |
| E9 | 45 | 42 | M | Pancreas | Duct adenocarcinoma | 2 | T3N0M0 | IIA | Malignant |
| F1 | 46 | 28 | F | Retroperitoneum | Epithelial malignant mesothelioma | * | T2N0M0 | II | Malignant |
| F2 | 47 | 33 | F | Retroperitoneum | Epithelial malignant mesothelioma | * | T4N0M0 | IV | Malignant |
| F3 | 48 | 50 | M | Pericardium | Epithelial malignant mesothelioma | * | T2N0M0 | II | Malignant |
| F4 | 49 | 57 | M | Prostate | Adenocarcinoma (Gleason grade:3, Gleason score:3+4) | * | T2N0M0 | II | Malignant |
| F5 | 50 | 64 | M | Prostate | Adenocarcinoma (Gleason grade:3, Gleason score:3+4) | * | T2N0M0 | II | Malignant |
| F6 | 51 | 46 | F | Skin | Malignant melanoma of thigh | * | T4N1M0 | III | Malignant |
| F7 | 52 | 60 | M | Skin | Malignant melanoma of right buttock | * | T4N1M0 | III | Malignant |
| F8 | 53 | 80 | M | Skin | Malignant melanoma of right sole of foot | * | T4N0M0 | IIB | Malignant |
| F9 | 54 | 65 | F | Thyroid gland | Medullary carcinoma | * | T3N1M0 | III | Malignant |
| G1 | 55 | 43 | M | Thyroid gland | Medullary carcinoma | * | T3N1M0 | III | Malignant | | Tissue Marker |
|
|
